Overexpression of treRNA1 in a CLL cell line led to reduced cell death, suggesting that treRNA1 decreases DNA damage and sensitivity to chemotherapy, thereby explaining the shorter PFS. Here, TRERNA1 is linked to B-cell chronic lymphocytic leukemia.